[{"data":1,"prerenderedAt":188},["ShallowReactive",2],{"drug-peramivir":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":34,"contraindications":79,"warnings":89,"renal":97,"monitoring":107,"interactions":108,"review":109,"examples":112,"atc":124,"iran":126,"usApproval":133,"links":139,"populations":154},"peramivir",1,{"fa":7,"en":8},"پرامیویر","Peramivir","anti-infectives",{"fa":11,"en":12},"مهارکننده نورآمینیداز (وریدی)","IV neuraminidase inhibitor",[14],{"name":15,"market":16},"Rapivab","US",[18,19,7],"rapivab","راپیواب",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":29,"refs":30},"vial-10","injection","iv","200 mg\u002F20 mL (10 mg\u002FmL) vial",{"amount":27,"unit":28,"perVolumeMl":5},10,"mg",[16],[31],{"source":32,"section":33},"fda-rapivab","3",[35,59],{"id":36,"disease":37,"label":38,"population":41,"type":45,"unit":28,"dose":46,"refs":48,"durationDays":51,"notes":52},"adult","influenza",{"fa":39,"en":40},"آنفلوانزای حاد بدون عارضه (۱۳ سال به بالا) — ۶۰۰ mg وریدی یک دوز ظرف ۲ روز از شروع علائم","Acute uncomplicated influenza (≥13 y) — 600 mg IV single dose within 2 days of symptom onset",{"minAge":42},{"value":43,"unit":44},13,"year","fixed",{"perDose":47,"dosesPerDay":5},600,[49],{"source":32,"section":50},"2.1",{"min":5,"max":5},[53],{"text":54,"refs":57},{"fa":55,"en":56},"انفوزیون دست‌کم ۱۵ دقیقه.","Infuse over at least 15 min.",[58],{"source":32,"section":50},{"id":60,"disease":37,"label":61,"population":64,"type":69,"unit":28,"dose":70,"refs":73,"limits":75,"durationDays":78},"child",{"fa":62,"en":63},"کودک ۶ ماه تا ۱۲ سال — ۱۲ mg\u002Fkg وریدی یک دوز (حداکثر ۶۰۰ mg)","Children 6 months–12 y — 12 mg\u002Fkg IV single dose (max 600 mg)",{"minAge":65,"maxAge":68},{"value":66,"unit":67},6,"month",{"value":43,"unit":44},"weightBased",{"perKgPerDose":71,"intervalHours":72},12,24,[74],{"source":32,"section":50},{"maxPerDose":47,"refs":76},[77],{"source":32,"section":50},{"min":5,"max":5},[80],{"id":81,"severity":82,"text":83,"refs":86},"hyper","block",{"fa":84,"en":85},"حساسیت جدی یا آنافیلاکسی به پرامیویر.","Serious hypersensitivity or anaphylaxis to peramivir.",[87],{"source":32,"section":88},"4",[90],{"text":91,"refs":94},{"fa":92,"en":93},"واکنش پوستی و حساسیتی شدید (SJS)؛ رویدادهای عصبی-روانی (به‌ویژه کودکان)؛ عفونت باکتریایی همزمان.","Serious skin\u002Fhypersensitivity reactions (SJS); neuropsychiatric events (especially children); bacterial co-infection.",[95],{"source":32,"section":96},"5",[98],{"egfrBelow":99,"severity":100,"text":101,"refs":104},50,"warn",{"fa":102,"en":103},"ClCr زیر ۵۰: کاهش دوز طبق جداول ۱ و ۲؛ همودیالیز پس از دیالیز.","CrCl \u003C50: reduce per Tables 1 and 2; haemodialysis — give after dialysis.",[105],{"source":32,"section":106},"2.2",[],[],{"status":110,"reviewer":111,"date":111},"unverified",null,[113,119],{"regimen":36,"formulation":22,"input":114,"expect":117},{"ageYears":115,"weightKg":116},40,70,{"perDose":47,"mlPerDose":118},60,{"regimen":60,"formulation":22,"input":120,"expect":122},{"ageYears":66,"weightKg":121},20,{"perDose":123,"mlPerDose":72},240,[125],"J05AH03",{"status":127,"refs":128},"not-found",[129],{"source":130,"section":131,"url":132},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Peramivir",{"kind":134,"refs":135,"id":138},"NDA",[136],{"source":32,"section":137},"SPL approval \u002F marketing category","NDA206426",[140,143,147,151],{"kind":141,"url":142,"label":138},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=206426",{"kind":144,"url":145,"label":146},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=fe04f6cd-e71c-4bd4-abac-97720bba2a0d","FDA Rapivab",{"kind":148,"url":149,"label":150},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa614062.html","Peramivir Injection",{"kind":152,"url":153,"label":125},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J05AH03",{"pregnancy":155,"lactation":164,"pediatric":172,"geriatric":180},{"level":156,"text":157,"quote":160,"refs":161},"caution",{"fa":158,"en":159},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Limited available data with RAPIVAB use in pregnant women are insufficient to determine a drug-associated risk of adverse developmental outcomes.",[162],{"source":32,"section":163},"8.1",{"level":156,"text":165,"quote":168,"refs":169},{"fa":166,"en":167},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of RAPIVAB in human milk, the effects on the breastfed infant, or the effects on milk production.",[170],{"source":32,"section":171},"8.2",{"level":156,"text":173,"quote":176,"refs":177},{"fa":174,"en":175},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of RAPIVAB for the treatment of influenza has been established in pediatric patients 6 months to 17 years of age.",[178],{"source":32,"section":179},"8.4",{"level":156,"text":181,"quote":184,"refs":185},{"fa":182,"en":183},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Clinical trials of RAPIVAB did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.",[186],{"source":32,"section":187},"8.5",1792444417014]